Oct 2026· Journal of Gastroenterology and Hepatology· 0 citations· 32 references
Medicine
TL;DR
Older age, alcohol, T2DM, chronic HBV infection, and obesity were associated with advanced fibrosis, and risk factors and noninvasive score performance varied in nonelder subjects.
Abstract
Background
AND
Aim
Steatotic liver disease (SLD) may lead to advanced liver diseases. We aimed to identify clinical risk factors for advanced fibrosis in pathology-proven SLD patients in a hepatitis B virus (HBV) endemic population, with emphasis on nonelder subjects.
Methods
Adult SLD patients diagnosed via pathology at National Taiwan University Hospital between June 2009 and December 2023 were recruited. Advanced fibrosis was defined as F2 to F4 fibrosis. Patients were stratified by age (< 50 years defined as nonelder), metabolic dysfunction-associated steatotic liver disease (MASLD), and HBV infection. Clinical risk factors for advanced fibrosis and at-risk steatohepatitis were investigated, and the predictive performance of noninvasive scores was examined.
Results
Among 223 pathology-proven SLD patients, older age (odds ratio [OR]: 1.04), alcohol consumption (OR: 5.77), type 2 diabetes mellitus (T2DM) (OR: 2.13), chronic HBV infection (OR: 2.52), and obesity (OR: 2.64) were independent risk factors for advanced fibrosis. In the nonelder subgroup, older age (OR: 1.10) and obesity (OR: 3.75) were significant. In the MASLD subgroup, older age (OR: 1.04), hypertension (OR: 2.31), T2DM (OR: 3.07), and chronic HBV infection (OR: 3.59) remained significant. Obesity (OR: 4.14) was a significant risk factor for at-risk steatohepatitis in the nonelder subgroup. NAFLD fibrosis score had the highest AUROC (0.724) for advanced fibrosis in the entire cohort, while FIB-4 performed best in nonelder subjects.
Conclusions
Older age, alcohol, T2DM, chronic HBV infection, and obesity were associated with advanced fibrosis. Risk factors and noninvasive score performance varied in nonelder subjects.
Background and Aims. Metabolic dysfunction–associated steatotic liver disease (MASLD) is an emerging cardiovascular risk factor. As patients with hemophilia (PWH) age and develop metabolic comorbidities, cardiovascular disease is becoming increasingly relevant despite their inherited bleeding tendency. In addition, liv...
C. Simion· Bleeding Thrombosis and Vasc...· 0 citations
BACKGROUND & AIMS
Cirrhosis from metabolic dysfunction-associated steatotic liver disease (MASLD) usually develops with advancing age, yet a subset of patients presents at younger ages. We examined genetic and metabolic factors associated with younger-onset MASLD cirrhosis.
APPROACH AND RESULTS
Adults with biopsy-pro...
Veeral H. Ajmera, Linus Schwantes-An, Luis Antonio Díaz et al.· Clinical Gastroenterology an...· 0 citations
BACKGROUND AND OBJECTIVE
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rising cause of chronic liver disease. Liver stiffness measurement (LSM) to assess disease stage is gaining popularity but can demonstrate heterogeneous results in clinical practice. Moreover, portal hypertension may develop...
Diederick J. van Doorn, L. Schoenmakers, S. de Jager et al.· JHEP Reports· 0 citations
In the precision therapy era, FIB-4 remains a scalable front-door test but should not serve as a stand-alone selector for drug eligibility; confirmatory staging is required to identify F2-F3 disease and exclude cirrhosis.
K. Soni, V. Jahagirdar, Omar Albhaisi et al.· Alimentary Pharmacology and...· 0 citations
The findings endorse the need for screening for liver fibrosis in T2DM patients, particularly those at increased risk, and suggest early detection and appropriate management are essential to prevent progression to advanced liver disease.
M. Almohammadi, Z. E. Alsadi, A. B. Alenezi et al.· PeerJ· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.